SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 41 filers reported holding SUNESIS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,000 | -37.5% | 20,033 | -0.1% | 0.00% | – |
| Q1 2020 | $8,000 | +14.3% | 20,058 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | -53.3% | 20,058 | -4.3% | 0.00% | – |
| Q3 2019 | $15,000 | 0.0% | 20,955 | +4.5% | 0.00% | – |
| Q2 2019 | $15,000 | -37.5% | 20,058 | 0.0% | 0.00% | – |
| Q1 2019 | $24,000 | – | 20,058 | +34482.8% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 58 | -98.1% | 0.00% | – |
| Q3 2018 | $6,000 | – | 3,085 | +5219.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 58 | -94.5% | 0.00% | – |
| Q1 2018 | $3,000 | -82.4% | 1,058 | -75.9% | 0.00% | – |
| Q4 2017 | $17,000 | +88.9% | 4,391 | 0.0% | 0.00% | – |
| Q3 2017 | $9,000 | -25.0% | 4,391 | 0.0% | 0.00% | – |
| Q2 2017 | $12,000 | -33.3% | 4,391 | 0.0% | 0.00% | – |
| Q1 2017 | $18,000 | +350.0% | 4,391 | +339.1% | 0.00% | – |
| Q4 2016 | $4,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |